If You Invested $1,000 in Compass Therapeutics Inc (CMPX)
This article analyzes the historical performance of investing $1,000 in Compass Therapeutics Inc (CMPX) over different periods, detailing the current worth of such an investment and its annual returns. It also provides a comprehensive overview of Compass Therapeutics, a clinical-stage oncology biopharmaceutical company, highlighting its scientific focus on antibody-based therapeutics, key product candidates like Tovecimig and CTX-8371, and its development in various oncology indications. The article emphasizes the company's strategy of targeting angiogenesis, immune regulation, and tumor growth through its proprietary pipeline.
Here’s Why Citizens Maintains a Buy on Compass Therapeutics (CMPX)
Citizens has reiterated a Market Outperform rating on Compass Therapeutics (CMPX) with a $10 price target after the company presented promising clinical data at the ASCO conference for its bispecific antibody, CTX-8371. This drug showed early signs of activity in treating difficult cancers. Upcoming catalysts for CMPX include an FDA meeting in August for Tovecimig and new data releases for CTX-8371 and CTX-10726 later in 2026.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Compass Thera
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Compass Therapeutics, Inc. (CMPX) following a significant drop in its stock price. The investigation stems from an April 27, 2026 announcement regarding a phase 2/3 study for its drug tovecimig, which, despite meeting a key secondary endpoint, missed another crucial one, overall survival, leading to a 64.41% stock price decline. Investors are encouraged to contact the firm for more information regarding this investigation.
Compass updates corporate presentation, reports positive Phase 2/3 COMPANION-002 BTC data and plans BLA engagement
Compass Therapeutics (`CMPX`) has updated its corporate presentation, revealing positive Phase 2/3 COMPANION-002 data for tovecimig in second-line biliary tract cancer (BTC). The data shows improved objective response rate (ORR) and progression-free survival (PFS) for a combination therapy. The company plans to engage with the FDA in Q3 2026 for a Biologics License Application (BLA) submission in late 2026.
Compass Therapeutics (NASDAQ: CMPX) targets BLA after biliary tract cancer trial success
Compass Therapeutics' tovecimig, in combination with paclitaxel, showed significant improvement in overall response rate (18.0% vs. 5.3%) and progression-free survival (4.7 months vs. 2.6 months) in a Phase 2/3 trial for second-line biliary tract cancer. The company plans an FDA meeting in Q3 2026 and a Biologics License Application (BLA) filing in Q4 2026, targeting potential approval in 2027 for a U.S. market estimated at over $3 billion. Compass also detailed its broader oncology pipeline and reported $195 million in cash, providing runway into 2028.
Bronstein, Gewirtz & Grossman, LLC Encourages Compass Therapeutic
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Compass Therapeutics, Inc. (CMPX) following a significant drop in its stock price. This decline occurred after the company announced phase 2/3 study results for its drug tovecimig, which met a key secondary endpoint but missed another crucial one related to overall survival. The law firm is encouraging investors who purchased Compass securities to inquire about a potential securities investigation.
Price to sales forward of Compass Therapeutics, Inc. – NASDAQ:CMPX
This page displays the "Price to sales forward" metric for Compass Therapeutics, Inc. (NASDAQ: CMPX) as provided by TradingView. The content primarily focuses on financial data for the company within the Pharmaceuticals: Major sector and indicates market closure with no current trades.
Enterprise value to revenue forward of Compass Therapeutics, Inc. – NASDAQ:CMPX
This article focuses on the "Enterprise value to revenue forward" metric for Compass Therapeutics, Inc. (NASDAQ: CMPX). The content is primarily a header with navigation and footer details, indicating a financial data point for the company on the TradingView platform.
Compass Therapeutics, Inc.(NasdaqCM:CMPX) dropped from Russell 3000E Growth Benchmark
Compass Therapeutics, Inc. (NasdaqCM:CMPX), a clinical-stage biopharmaceutical company focused on oncology therapeutics, has been dropped from the Russell 3000E Growth Benchmark. The company's stock shows a 5-day change of +0.48% and a year-to-date change of -61.27%. Compass Therapeutics is developing antibody-based therapeutics, with lead candidates like tovecimig and CTX-471 targeting various pathways for anti-tumor responses.
Compass Therapeutics, Inc.(NasdaqCM:CMPX) dropped from Russell Small Cap Comp Growth Benchmark
Compass Therapeutics, Inc. (NasdaqCM:CMPX) has been removed from several Russell benchmarks, including the Russell Small Cap Comp Growth Benchmark, Russell 3000 Growth Benchmark, and Russell Microcap Growth Benchmark Index. This news follows a recent downgrade by Raymond James and a lowered price target by Wedbush after the company's Tovecimig study failed to meet its overall survival endpoint in biliary tract cancer, causing its shares to fall. The company is a clinical-stage oncology biopharmaceutical company developing antibody-based therapeutics.
Compass Therapeutics, Inc. Actuals & Estimates (NASDAQ:CMPX)
This article provides an overview of Compass Therapeutics, Inc. (NASDAQ:CMPX) stock data, including its current price, historical performance, and analyst forecasts. It also details the company's financial actuals and estimates, discusses upcoming earnings reports, and provides answers to frequently asked questions about investing in CMPX.
CMPX Forecast — Price Target — Prediction for 2027
This article provides a forecast and price target for Compass Therapeutics, Inc. (CMPX) stock for 2027 based on analyst opinions. It includes current stock performance, historical highs and lows, volatility metrics, and key financial information like recent earnings, revenue, and employee count. The article also addresses frequently asked questions regarding purchasing CMPX stock and its investment outlook.
Compass Therapeutics Inc. (CMPX) Valuation: PE, PB & Fair Value Analysis
This article provides a valuation analysis for Compass Therapeutics Inc. (CMPX), highlighting its current valuation score, market capitalization, and P/E ratio. As of June 26, 2026, the company's valuation score is 8.69, ranking 104 out of 387 in the Biotechnology & Medical Research industry. The article notes that relevant data for P/B, P/S, and P/CF ratios have not yet been disclosed by the company.
Compass Therapeutics (CMPX) Stock Forecast & Analyst Ratings
This article provides a stock forecast and analyst ratings for Compass Therapeutics (CMPX). It serves as a resource for investors looking for insights into the company's financial prospects and market sentiment.
Compass Therapeutics Inc. (CMPX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a revenue breakdown for Compass Therapeutics Inc. (CMPX), noting that essential financial data such as business segments, regional revenue, and profit contribution have not yet been disclosed by the company. It only shows a placeholder for "United States" with zero revenue and proportion. The page displays current stock information and market capitalization for CMPX.
How Compass Therapeutics (CMPX) Is Moving Tovecimig Toward a Potential Biliary Tract Cancer Filing
Compass Therapeutics (CMPX) is advancing its experimental cancer treatment, tovecimig, for biliary tract cancer, having received FDA Orphan Drug Designation and planning an approval application later in 2026. The company reported strong tumor response in late-stage studies and has sufficient funding into 2028 to pursue regulatory steps and develop other pipeline assets. Additionally, Compass has initiated a Phase 1 study for another experimental treatment, CTX-10726, with initial data expected in late 2026.
Compass Therapeutics Inc. (CMPX) Financial Health: Profitability & Balance Sheet Analysis
This article provides an analysis of Compass Therapeutics Inc. (CMPX) financial health, highlighting its current financial score of 6.36, which ranks it 257 out of 388 in the Biotechnology & Medical Research industry. While the company's financial status is considered robust, its operating efficiency is low. The report also notes that relevant financial data for sections like Quality of Earnings, Operational Efficiency, Growth Potential, and Shareholder Returns have not yet been disclosed by the company.
Compass Therapeutics Inc. (CMPX) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Compass Therapeutics Inc. (CMPX), detailing its current price momentum score, support and resistance levels, and indicator readings (MACD, RSI, KDJ, etc.) and moving averages. According to the analysis, CMPX currently has a price momentum score of 6.99 and shows an overall "Sell" signal based on its technical indicators and moving averages. The stock is trading between a resistance level of $2.38 and a support level of $1.66.
Compass Therapeutics Inc. (CMPX) Earnings Forecast: Future EPS & Revenue Growth Estimates
This article provides an earnings forecast for Compass Therapeutics Inc. (CMPX), highlighting its current earnings forecast score of 8.67 and ranking within the Biotechnology & Medical Research industry. It details analyst ratings, revealing a strong "Buy" consensus with an average price target of $10.00, and includes expected EPS for the next quarter. The report also offers peer comparisons and addresses FAQs regarding price targets and recent EPS performance.
5 Small Cap Stocks with Potential to Rise 1000 Percent
This article highlights Compass Therapeutics, Inc. (NASDAQ: CMPX) as a small-cap stock with significant growth potential, possibly rising 1000 percent. The company is developing tovecimig, an experimental cancer treatment that recently received FDA Orphan Drug Designation and showed promising results in late-stage studies for biliary tract cancer. Compass Therapeutics also has a strong cash position, expecting to fund operations into 2028, and is advancing other experimental treatments.
Compass Therapeutics Shareholders Back Directors, Pay, Auditor Oversight
Compass Therapeutics, Inc. shareholders recently re-elected two Class III directors, Thomas J. Schuetz and Richard S. Lindahl, and ratified CohnReznick, LLP as their independent auditor. Investors also approved the compensation for executive officers and supported an annual advisory vote on executive pay, indicating strong shareholder engagement. Despite these governance advancements, TipRanks' AI Analyst Spark views CMPX as "Neutral" due to weak financial performance and a challenging technical outlook for the pre-revenue company.
Transcript : Compass Therapeutics, Inc. Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-09-2026 08
This article is a transcript of Compass Therapeutics, Inc.'s presentation at the Goldman Sachs 47th Annual Global Healthcare Conference held on June 9, 2026. The presentation started at 8:00 AM. The full article content is reserved for subscribers.
Compass Therapeutics (NASDAQ: CMPX) investors back board, auditor and pay in 2026 votes
Compass Therapeutics, Inc. stockholders approved all proposals at their annual meeting on June 10, 2026. This included re-electing Class III directors Thomas J. Schuetz and Richard S. Lindahl, ratifying CohnReznick LLP as the independent auditor, and approving executive compensation on a non-binding basis. Additionally, shareholders voted to hold future advisory votes on executive compensation annually.
CMPX: Lead oncology asset tovecimig nears FDA filing after strong BTC trial results; multiple catalysts ahead
Compass Therapeutics (CMPX) is advancing four oncology assets, with its lead drug, tovecimig, showing strong efficacy in BTC and nearing FDA submission. The company anticipates multiple clinical and regulatory catalysts within the next year and has a cash runway extending into 2028. This information comes from an AI-generated summary of Compass Therapeutics' presentation at the Goldman Sachs 47th Annual Global Healthcare Conference 2026.
Compass Therapeutics Eyes FDA Path After Tovecimig Trial Win
Compass Therapeutics is preparing for an FDA meeting in early August regarding its drug tovecimig, a DLL4/VEGF bispecific antibody, after successful trial results in advanced biliary tract cancer. The COMPANION-002 study met its primary endpoint of overall response rate and significantly improved progression-free survival. The company aims for a rolling Biologics License Application submission by early next year, with potential for priority review due to the drug's strong clinical endpoints and significant reduction in disease progression risk.
Analysts Offer Insights on Healthcare Companies: Praxis Precision Medicines (PRAX), Compass Therapeutics (CMPX) and Tenax Therapeutics (TENX)
This article highlights bullish sentiments from three analysts regarding several healthcare companies. Douglas Tsao from H.C. Wainwright reiterated a Buy rating on Praxis Precision Medicines (PRAX) with a $1245.00 price target. Biren Amin from Piper Sandler maintained a Buy rating on Compass Therapeutics (CMPX) with a $4.00 price target. Yasmeen Rahimi, also from Piper Sandler, upheld a Buy rating on Tenax Therapeutics (TENX) and set a price target of $20.00.
Stifel Maintains Compass Therapeutics(CMPX.US) With Buy Rating, Maintains Target Price $6
Stifel has reiterated its Buy rating for Compass Therapeutics (CMPX.US) and maintained its price target of $6. The article indicates a continued positive outlook from the financial firm regarding the company's stock.
Stifel reiterates Compass Therapeutics stock rating on ASCO data
Stifel maintained its Buy rating and $6.00 price target for Compass Therapeutics (NASDAQ:CMPX) after ASCO meeting data, noting the resilience of the CTX-8371 bispecific antibody in pretreated patients, despite current overvaluation according to InvestingPro. The firm anticipates further efficacy data from dose-expansion studies by year-end 2026 and remains positive on tovecimig for biliary tract cancer. This comes amidst mixed analyst reactions to recent trial results, with Raymond James downgrading, while Citizens and H.C. Wainwright maintained positive ratings.
Piper Sandler Maintains Compass Therapeutics(CMPX.US) With Buy Rating, Cuts Target Price to $4
Piper Sandler has reiterated its Buy rating for Compass Therapeutics (CMPX.US) but has lowered the price target to $4. This adjustment reflects a revised outlook while still signaling confidence in the company's prospects.
Stifel reiterates Compass Therapeutics stock rating on ASCO data By Investing.com
Stifel maintained its Buy rating and a $6.00 price target for Compass Therapeutics following the release of new ASCO clinical trial data for CTX-8371. The firm noted promising durability and safety in heavily pretreated patients, despite the stock potentially being overvalued according to InvestingPro analysis. While other analysts like Raymond James downgraded the stock due to trial delays, H.C. Wainwright reaffirmed a Buy rating, indicating mixed analyst sentiment on Compass Therapeutics' recent outcomes.
Stifel reiterates Compass Therapeutics stock rating on ASCO data By Investing.com
Stifel maintained its Buy rating and $6.00 price target for Compass Therapeutics (NASDAQ:CMPX) after the presentation of clinical trial data at the ASCO meeting. The firm highlighted the durability of responses and the safety profile of CTX-8371, a bispecific antibody, in heavily pretreated cancer patients. Despite an InvestingPro analysis suggesting the stock might be overvalued, Stifel anticipates further clarity on efficacy from additional dose-expansion data later in 2026.
Number of shareholders of Compass Therapeutics, Inc. – NASDAQ:CMPX
This article focuses on providing information about the number of shareholders for Compass Therapeutics, Inc. (NASDAQ: CMPX). It does not contain specific shareholder numbers but serves as a placeholder or financial data point on the TradingView platform. The content primarily highlights the navigation and structure of the TradingView website with references to market data providers.
Biotech Compass Therapeutics to present at Jefferies and Goldman Sachs events
Compass Therapeutics (Nasdaq: CMPX) will participate in two June 2026 investor conferences: the Jefferies Global Healthcare Conference on June 4th and the Goldman Sachs 47th Annual Global Healthcare Conference on June 9th. The company's management will present at both events, with webcasts and replays available for interested investors. The stock saw a positive market reaction of +6.17% following the news of these upcoming presentations.
Compass Therapeutics to Participate in Upcoming June Investor Events
Compass Therapeutics, Inc. (Nasdaq: CMPX), an oncology-focused biopharmaceutical company, announced its participation in two investor events in June. The company will attend the Jefferies Global Healthcare Conference on June 4, 2026, and the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, 2026. Management will be available for one-on-one meetings at both events, and presentation webcasts will be archived online.
Compass Therapeutics to Participate in Upcoming June Investor Events
Compass Therapeutics, Inc. announced its participation in two investor events in June: the Jefferies Global Healthcare Conference on June 4, 2026, and the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, 2026. Management will be available for one-on-one meetings, and presentations will be archived online. The company, based in Boston, MA, is a clinical-stage biopharmaceutical firm focused on oncology, developing antibody-based therapeutics.
Compass Therapeutics to Participate in Upcoming June Investor Events
Compass Therapeutics, Inc. (Nasdaq: CMPX) will participate in two upcoming investor events in June: the Jefferies Global Healthcare Conference on June 4, 2026, and the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, 2026. Management will be available for one-on-one meetings at both events, and presentations will be archived online. The company is a clinical-stage biopharmaceutical firm focused on developing antibody-based therapeutics for oncology.
Compass Therapeutics Announces Promising Phase 1 Results for CTX-8371, Innovative Dual Checkpoint Blocker in Advanced Malignancies
Compass Therapeutics announced promising Phase 1 results for its dual checkpoint blocker, CTX-8371, in patients with advanced cancers resistant to prior immune checkpoint inhibitors. The study revealed deep and durable responses, particularly in triple-negative breast cancer, Hodgkin lymphoma, and non-small cell lung cancer, along with a favorable safety profile. The company plans to expand patient cohorts for these malignancies and expects to release additional data in late 2026.
Compass cancer drug shows lasting responses in small Phase 1 trial
Compass Therapeutics' investigational cancer drug, CTX-8371, a dual PD-1×PD-L1 bispecific antibody, demonstrated promising clinical activity in a Phase 1 trial for advanced malignancies that had failed prior immune checkpoint inhibitors. The study reported deep and durable responses in patients with triple-negative breast cancer, Hodgkin lymphoma, and non-small cell lung cancer, with a 33% overall response rate at higher doses and no dose-limiting toxicities. The company plans to present full data at the 2026 ASCO Annual Meeting and has initiated cohort expansions for these cancer types, with more data expected in Q4 2026.
Compass Therapeutics to Present Promising Phase 1 Clinical Data for CTX-8371 in Patients With Advanced Malignancies Treated in the Post-Checkpoint Inhibitor Setting at the 2026 ASCO Annual Meeting
Compass Therapeutics will present promising Phase 1 clinical data for its drug CTX-8371 at the 2026 ASCO Annual Meeting. The data concerns patients with advanced malignancies who were previously treated with checkpoint inhibitors. This presentation highlights the potential of CTX-8371 in a challenging patient population.
Compass Therapeutics to Present Promising Phase 1 Clinical Data for CTX-8371 in Patients with Advanced Malignancies Treated in the Post-Checkpoint Inhibitor Setting at the 2026 ASCO Annual Meeting
Compass Therapeutics will present promising Phase 1 clinical data for CTX-8371, a novel PD-1×PD-L1 bispecific antibody, at the 2026 ASCO Annual Meeting. The data highlights deep and durable responses in patients with advanced malignancies—specifically triple-negative breast cancer, Hodgkin lymphoma, and non-small cell lung cancer—who were resistant to prior immune checkpoint inhibitors, showing favorable safety with no dose-limiting toxicities. The company has initiated cohort expansions for these malignancies and expects to report additional data in Q4 2026.
Compass Therapeutics reports phase 1 data for CTX-8371
Compass Therapeutics announced positive phase 1 data for its bispecific antibody CTX-8371 in advanced cancer patients, showing responses in triple-negative breast cancer, Hodgkin lymphoma, and non-small cell lung cancer. Despite these clinical results, the company's stock has declined significantly year-to-date, and analysts have mixed opinions on its prospects following recent study data for another drug candidate, tovecimig. The new CTX-8371 data will be presented at the American Society of Clinical Oncology Annual Meeting on May 30, 2026.
Compass Therapeutics to Present Promising Phase 1 Clinical Data for CTX-8371 in Patients with Advanced Malignancies Treated in the Post-Checkpoint Inhibitor Setting at the 2026 ASCO Annual Meeting
Compass Therapeutics will present promising Phase 1 clinical data for its novel dual checkpoint blocker, CTX-8371, at the 2026 ASCO Annual Meeting. The drug showed deep and durable responses in patients with advanced cancers like triple-negative breast cancer, Hodgkin lymphoma, and non-small cell lung cancer, particularly those resistant to prior immune checkpoint inhibitors. CTX-8371 was also well-tolerated with a favorable safety profile, leading to planned cohort expansions for further data reporting in Q4 2026.
Compass Therapeutics to Present Promising Phase 1 Clinical Data for CTX-8371 in Patients with Advanced Malignancies Treated in the Post-Checkpoint Inhibitor Setting at the 2026 ASCO Annual Meeting
Compass Therapeutics will present promising Phase 1 clinical data for CTX-8371, a novel PD-1×PD-L1 bispecific antibody, at the 2026 ASCO Annual Meeting. The data show that CTX-8371 demonstrated clinical activity and was well-tolerated in patients with advanced malignancies resistant to prior immune checkpoint inhibitors, including deep and durable responses in triple-negative breast cancer, Hodgkin lymphoma, and non-small cell lung cancer. The company plans to initiate cohort expansions in these malignancies, anticipating further data by Q4 2026.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass Therapeutics, Inc. - CMPX
Pomerantz LLP is investigating potential securities fraud claims against Compass Therapeutics, Inc. (NASDAQ: CMPX) on behalf of its investors. The investigation follows a significant 64.41% drop in Compass's stock price on April 27, 2026, after the company announced phase 2/3 study results for its drug tovecimig, which met a key secondary endpoint but missed another vital endpoint, overall survival. Investors who suffered losses are encouraged to contact the firm.
CMPX News | COMPASS THERAPEUTICS INC (NASDAQ:CMPX)
This page provides recent news and analysis for COMPASS THERAPEUTICS INC (NASDAQ:CMPX). Key updates include the company reporting a wider Q2 2025 loss, plans to present Phase 1 clinical data for CTX-8371 at the 2026 ASCO Annual Meeting, and multiple investor alerts from Pomerantz LLP investigating claims on behalf of Compass Therapeutics investors. The stock price was 2.07 USD at close on May 22, 2026.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass ...
Pomerantz LLP is investigating potential securities fraud claims against Compass Therapeutics, Inc. (NASDAQ: CMPX) on behalf of investors. This investigation follows a significant drop in Compass's stock price after the company announced phase 2/3 study results for its drug tovec. While the study met a key secondary endpoint, it missed another key secondary endpoint for overall survival, leading to a 63.61% stock decrease on April 26, 2026.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass Therapeutics, Inc. - CMPX
Pomerantz LLP is investigating potential securities fraud claims against Compass Therapeutics, Inc. (NASDAQ:CMPX) following a significant drop in its stock price. This decline occurred after the company announced phase 2/3 study results for its drug tovecimig, which, despite meeting a key secondary endpoint, missed another crucial one related to overall survival. Investors are encouraged to contact the firm regarding their legal rights.
Compass Therapeutics (CMPX) Reports Q1 2026 Net Loss of $18.3M
Compass Therapeutics (CMPX) reported a Q1 2026 net loss of $18.3 million, or $0.10 per share, with increased R&D and G&A expenses. The company holds $195 million in cash, providing a capital runway into 2028. Key developments include advancing tovecimig for biliary tract cancer with an upcoming BLA submission and FDA meeting, and initiating studies for CTX-8371, CTX-10726, and CTX-471.
5 Best NASDAQ Stocks Under $5 to Buy Right Now
The article lists the top 5 NASDAQ stocks under $5 to consider buying. It highlights Compass Therapeutics Inc. (NASDAQ: CMPX) as one such stock, detailing its recent financial performance, R&D activities, and clinical trial progress for various oncology treatments, including orphan drug designation for tovecimig. The company reports a capital runway into 2028 and has several studies underway.
Compass Therapeutics (CMPX) price target decreased by 26.39% to 10.11
This article reports a significant 26.39% decrease in the price target for Compass Therapeutics (CMPX), bringing it down to $10.11. The financial adjustment suggests a revised outlook on the company's future performance or valuation.
